CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics

SOUTH SAN FRANCISCO & OAKLAND, Calif.–(BUSINESS WIRE)–CERo Therapeutics, Inc. (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, and Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) (“PBAX”), a special purpose acquisition company formed for the purpose of acquiring or merging with…

Advertisement — Advertise with Biotech Networks